Your browser doesn't support javascript.
loading
Cervical cancer in Region Skåne, Sweden 2017-2020 after the implementation of primary HPV screening: A quality assurance audit.
Hellsten, Caroline; Holmberg, Anna; Astrom, Jennica; Forslund, Ola; Borgfeldt, Christer.
Affiliation
  • Hellsten C; Department of Obstetrics and Gynecology, Skåne University Hospital, Department of Clinical Science Lund, Lund University, Lund, Sweden.
  • Holmberg A; Department of Obstetrics and Gynecology, Skåne University Hospital, Department of Clinical Science Lund, Lund University, Lund, Sweden.
  • Astrom J; Department of Obstetrics and Gynecology, Skåne University Hospital, Department of Clinical Science Lund, Lund University, Lund, Sweden.
  • Forslund O; Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Borgfeldt C; Clinical Microbiology, Infection Prevention and Control, Office for Medical Services, Region Skåne, Sweden.
Acta Obstet Gynecol Scand ; 103(1): 129-137, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37817563
ABSTRACT

INTRODUCTION:

Primary human papilloma virus (HPV) screening to detect cervical cancer and dysplastic lesions was implemented in Region Skåne 2017 for women aged 30-70. The aim of this study was to characterize the screening history of women diagnosed with cervical cancer to evaluate the performance of the screening program, as well as to assess the cancer treatments given and shortcomings in the follow-up of women with cervical dysplasia. MATERIAL AND

METHODS:

We performed a quality assurance audit. The data was collected from the National Cervical Cancer Prevention Registry, Region Skåne Labmedicin database and the Melior Journal system in 2017-2020.

RESULTS:

We identified 247 women diagnosed with invasive cervical cancer in Region Skåne in 2017-2020. Of these, 35 (14.2%) had a screening history over at least two screening rounds before diagnosis. There were 25 (10.1%) women diagnosed with cervical cancer in between screening intervals, i.e., interval cancer. The most common screening history in women with cervical cancer was irregular screening (143, 57.9%), followed by women being above screening age (44, 17.8%). HPV was detected in 96% of the cases, either in cervical cytology or in the tumor tissue. The screening program detected the disease in 96 (38.9%) of the patients, 149 (60.3%) were diagnosed through symptoms and two (0.80%) as a result of incidental findings.

CONCLUSIONS:

The most powerful tool in the prevention of cervical cancer is screening program attendance. Prolongation with HPV screening among elderly women will also reduce the incidence of cervical cancer. Today, such cancers are usually discovered when symptoms appear.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Dysplasia / Uterine Cervical Neoplasms / Papillomavirus Infections Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Acta Obstet Gynecol Scand Year: 2024 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Dysplasia / Uterine Cervical Neoplasms / Papillomavirus Infections Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Acta Obstet Gynecol Scand Year: 2024 Document type: Article Affiliation country: Sweden